Buku Panduan Jabatan Patologi 2018 HRPZ II
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Senarai Singkatan Perpustakaan Di Malaysia
F EDISI KETIGA SENARAI SINGKATAN PERPUSTAKAAN DI MALAYSIA Edisi Ketiga Perpustakaan Negara Malaysia Kuala Lumpur 2018 SENARAI SINGKATAN PERPUSTAKAAN DI MALAYSIA Edisi Ketiga Perpustakaan Negara Malaysia Kuala Lumpur 2018 © Perpustakaan Negara Malaysia 2018 Hak cipta terpelihara. Tiada bahagian terbitan ini boleh diterbitkan semula atau ditukar dalam apa jua bentuk dengan apa cara jua sama ada elektronik, mekanikal, fotokopi, rakaman dan sebagainya sebelum mendapat kebenaran bertulis daripada Ketua Pengarah Perpustakaan Negara Malaysia. Diterbitkan oleh: Perpustakaan Negara Malaysia 232, Jalan Tun Razak 50572 Kuala Lumpur 03-2687 1700 03-2694 2490 03-2687 1700 03-2694 2490 www.pnm.gov.my www.facebook.com/PerpustakaanNegaraMalaysia blogpnm.pnm.gov.my twitter.com/PNM_sosial Perpustakaan Negara Malaysia Data Pengkatalogan-dalam-Penerbitan SENARAI SINGKATAN PERPUSTAKAAN DI MALAYSIA – Edisi Ketiga eISBN 978-983-931-275-1 1. Libraries-- Abbreviations --Malaysia. 2. Libraries-- Directories --Malaysia. 3. Government publications--Malaysia. I. Perpustakaan Negara Malaysia. Jawatankuasa Kecil Senarai Singkatan Perpustakaan di Malaysia. 027.002559 KANDUNGAN Sekapur Sirih .................................................................................................................. i Penghargaan .................................................................................................................. ii Prakata ........................................................................................................................... iii -
0. GUT 2018 S. Programme & Abstract Book Cover
Annual Scientific Meeting of the Malaysian Society of Gastroenterology & Hepatology For healthcare professional only Please consult local full prescribing information before prescribing. Further information available on request Headache, abdominal pain, constipation, diarrhea, flatulence, nauswa/vomiting. Undesirable effects: is not recommended. If unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. esomeprazole 20 mg should not be exceeded. Precautions: Hypersensitivity to the active substance esomeprazole or to other substituted benzimidazoles or to any of the excipients, nelfinavir. Exclude gastric malignancy prior to treatment Co-administation of esomeprazole with atazanavir Contraindications: administered as a bolus infusion over 30 minutes, followed by a continuous intravenous infusion of 8 mg/h given over 3 days (72 hours). The parenteral treatment period should be followed by oral acid suppression therapy. be given for up to 10 days as part of a full treatment period for the specified indications. Prevention of rebleeding of gastric and duodenal ulcers: following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be oesophagitis: 40 mg once daily. Reflux disease (symptomatic treatment): 20mg once daily. Healing of gastric ulcer and prevention of gastric and duodenal ulcer associated with NSAID therapy: 20mg once daily. Treatment with Nexium IV can Dosege: ulcer associated with NSAID therapy and prevention of gastric and duodenal ulcer associated with NSAID therapy. Prevention of rebleeding following therapeutic enddoscopy for acute bleeding gastric or duodenal ulcers. reflux (Esomeprazole) Indications: Nexium 40 mg injection/Infusion. When oral route is not possible or appropriate; treatment of gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux, healing of gastric ® nausea/vomiting. -
Penyata Rasmi Parlimen Parliamentary Deb Ates
Jilid I (,r4JTJ T Hari Rabu AI Bil, 31 4jJJi t \K 18hb Julai, 1979 PENYATA RASMI PARLIMEN PARLIAMENTARY DEB ATES DEWAN NEGARA SENATE PARLIMEN KELIMA Fifth Parliament PENGGAL PERTAMA First Session KANDUNGANNYA JAWAPAN-JAWAPAN MULUT BALI PERTANYAAN-PERTANYAAN [Ruangan 3045] USUL: Waktu Mesyuarat dan Urusan yang dibebaskan daripada Peraturan Mesyuarat [Ruangan 3080] RANG UNDANG-UNDANG: Rang Undang-undang Penyelarasan Perindustrian (Pindaan) [Ruangan 3081] Rang Undang-undang Peruntukan Diraja (Pindaan) [Ruangan 31091 Rang Undang-undang Pencen Khas (Raja Permaisuri Agong) [Ruangan 3121] Rang Undang-undang Saraan Hakim (Pindaan) (No. 2) [Ruangan 31331 MALAYSIA PARLIMEN KELIMA-DE WAN NEGARA Penyata Rasmi Parlimen PENGGAL YANG PERTAMA AHLI-AHLI DEWA'rT NEGARA Yang Berhormat Tuan Yang di -Pertua, TUN DATO' HAJI OMAR YOKE-LIN ONG, P.M.N., S.P.M.S ., D.P.M.S . (Dilantik). „ Menteri Tak Berpotfolio, DATO' HAJI MOHAMED BIN NASIR, S. P.M.K., J.M.N., J.P. (Kelantan). „ Menteri Tak Berpotfolio, PENGIRAN OTHMAN BIN HAJI PENGIRAN RAUF (Sabah). „ Tuan (Timbalan) Yang di-Pertua, TAN SRI DATUK S. 0. K. UBAIDULLA, P.S.M., D.P.M.S., J.M.N. (Dilantik). „ Setiausaha Parlimen Kementerian Sains, Teknologi dan Alam Sekitar, TUAN LAW HIENG DING (Dilantik). „ Jeneral TAN SRI HAJI ABDUL HAMID BIN BIDIN, P.S.M., S.P.M.K., D.I.M.P., J.M.N., P.M.P., P.P.T., P.J.K. (Dilantik). „ TUAN HAJI ABDUL LATIP BIN HAJI IDRIS (Dilantik). „ TUAN ABDUL RAZAK BIN ABU SAMAH (Dilantik). „ TAN SRI DATUK HAJI ABDUL RAZAK BIN HAJI HUSAIN, P.S.M., D.S.W., J.S.M., S.M.P. -
Malaysian Journal of Pharmacy (Vol 2 Issue 2)
PP12684/8/2008 Vol. 2 Issue 2. August 2016 MALAYSIAN JOURNAL of PHARMACY In this issue: Supplement • Proceedings of the 9th National Pharmacy R&D Conference 2016 A Publication of the Malaysian Pharmaceutical Society PP12684/8/2008 Vol. 2 Issue 2. August 2016 MALAYSIAN JOURNAL of PHARMACY In this issue: Supplement • Proceedings of the 9th National Pharmacy R&D Conference 2016 A Publication of the Malaysian Pharmaceutical Society PP12684/8/2008 Vol. 2 Issue 2. August 2016 MALAYSIAN JOURNAL of PHARMACY In this issue: Supplement • Proceedings of the 9th National Pharmacy R&D Conference 2016 A Publication of the Malaysian Pharmaceutical Society EDITORIAL BOARD Malaysian Journal of Pharmacy Vol. 2 Issue 2. August 2016 The Official Journal of the Malaysian Pharmaceutical Society Editor-in-Chief: Assoc Prof Dr Asrul Akmal Shafie Managing Editor: Mr Ho Rhu Yann International Advisory Board: Assoc Prof Dr Chua Siew Siang Prof Dr Mohd Baidi Bahari Associate Editors: Mr Lam Kai Kun Prof Dr Mohamed Azmi Ahmad Hassali Assoc Prof Dr Mohamad Haniki Nik Mohamed Ms Syireen Alwi Prof P T Thomas Dr Wong Tin Wui Assoc Prof Dr Vikneswaran a/l Murugaiyah Prof Dr Yuen Kah Hay Publisher: Malaysian Pharmaceutical Society Malaysian Journal of Pharmacy 16-2 Jalan OP 1/5, 1-Puchong Business Park (the official journal of the Malaysian Off Jalan Puchong Pharmaceutical Society) 47160 Puchong c/o School of Pharmaceutical Sciences Malaysia Universiti Sains Malaysia Tel: 6-03-80791861 11800 Penang Fax: 6-03-80700388 MALAYSIA Homepage: www.mps.org.my Email: [email protected] Email: [email protected] The Malaysian Journal of Pharmacy is a publication of the Malaysian Pharmaceutical Society. -
NATIONAL OBSTETRICS REGISTRY 4Th REPORT
NATIONAL OBSTETRICS REGISTRY - 0 - - - - - 5 - - - - - 10 = = - - - 15 Editors: Ravichandran Jeganathan Shamala Devi Karalasingam A publication of the National Obstetrics Registry and the Clinical Research Centre, Ministray of Health Malaysia NATIONAL OBSTETRICS REGISTRY (NOR) 4th REPORT JAN 2013 – DEC 2015 Editors: Ravichandran Jeganathan Shamala Devi Karalasingam A publication of the National Obstetrics Registry and the Clinical Research Centre, Ministry of Health Malaysia December 2017© National Obstetrics Registry Publisher: Jointly published by the National Obstetrics Registry and the Clinical Research Centre (CRC), Ministry of Health Malaysia. Contact Details: National Obstetrics Registry National Clinical Research Centre 3rd Floor, Dermatology Block General Hospital Kuala Lumpur Jalan Pahang, 50586 Kuala Lumpur, Malaysia. Tel : (603) 40439300/26980310 Fax : (603) 40439500/29911682 Email : [email protected] Website : http://www.acrm.org.my/nor Suggested citation: Ravichandran Jeganathan (Eds). Preliminary Report of National Obstetrics Registry, Jan 2013 – Dec 2015. Kuala Lumpur, Malaysia: National Obstetrics Registry 2013-2015 Disclaimer: Data reported in this report were collected for 3 years period (from Jan 2013 to December 2015). This report is copyrighted. Reproduction and dissemination of this report in part or in whole for research, educational or other non- commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Electronic version The electronic version of this report may be downloaded at or http://www.crc.gov.my/publication/report. Funding The National Obstetrics Registry is funded with grants from the Ministry of Health Malaysia (MOH) ISSN No i ACKNOWLEDGEMENT The National Obstetrics Registry (NOR) team would like to give its grateful appreciation to everyone who has helped make this report possible. -
Csamm 2016 Abstract Book
CONTENTS 13TH MAY 2016 (FRIDAY) MEET-THE-EXPERTS 1 | Hepatobiliary Advances in understanding acute pancreatitis and their implications – John Windsor (New Zealand) MEET-THE-EXPERTS 2 Controversies in breast conserving surgery – Elisabeth Elder (Australia), Supakorn Rojananin (Thailand), Farhana Fadzli (Malaysia) PLENARY 1 | Keynote Lecture The delivery of health services for tomorrow’s Malaysia: – Challenges and solutions Noor Hisham Abdullah (Director-General of Health, Malaysia) 43RD A M ISMAIL ORATION An unforgettable surgical journey 12 J C Mehta SYMPOSIUM 1 | Colorectal – Beware Greeks Bearing Gifts 1.1 Anastomotic leak: The do’s and don’ts – Akhtar Qureshi (Malaysia) 1.2 Is radical surgery still necessary? The role of fluorescence 13 imaging in intraoperative colorectal cancer staging David Jayne (UK) 1.3 Obstetric anal sphincter injuries (OASIS): Role of the 13 colorectal surgeon Monica Millan (Spain) 1.4 When surgical colleagues ask a favour…Re-operative – surgery for haemorrhoids Ismail Sagap (Malaysia) 1.5 Surgery for advanced colorectal cancer: How far should – one go? Melissa Teo (Singapore) 1 CONTENTS 13TH MAY 2016 (FRIDAY) SYMPOSIUM 2 | Breast Surgery – Less Is More: Last Of The Amazons 2.1 Dilemmas in surgical management of early breast cancer – Yip Cheng Har (Malaysia) 2.2 Risk-reducing mastectomy – Who and how – Elisabeth Elder (Australia) 2.3 Controversies in the management of metastatic breast cancer – Supakorn Rojananin (Thailand) SYMPOSIUM 3 | Vascular – Devil’s Advocate 3.1 The challenges of being a vascular surgeon -
Clinical Trial Protocol
DNDi-SOF/RDV-01-HCV Protocol version 8.0 dated 18 Mar 2020 CLINICAL TRIAL PROTOCOL Open label phase II/III, multicenter, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia Short title Strategic transformation of the market of HCV treatments (STORM-C-1) Name of product(s) Sofosbuvir 400 mg tablet manufactured by European Egyptian Pharmaceutical Industries (EEPI), Egypt Ravidasvir 200 mg tablet manufactured by Doppel Farmaceutici, Italy Drug Class HCV Direct Acting Agents Antivirals (DAAs) Sofosbuvir (SOF): NS5 B polymerase nucleotide inhibitor Ravidasvir (RDV, formerly PPI-668): NS5 A replication complex inhibitor Phase Phase II/III Indication Chronic Hepatitis C infection [+/- HIV co-infection] Clinical Trial Protocol DNDi-SOF/RDV-01-HCV Number EudraCT Not applicable Co-Sponsors Drugs for Neglected Diseases initiative (DNDi) Ministry of Health Malaysia Ministry of Public Health Thailand National Science and Technology Development Agency (NSTDA) Thailand National Coordinating Thailand: Malaysia: Investigator Dr. Sombat Thanprasertsuk (stage 1) Dr. Soek-Siam Tan Dr. Satawat Thongsawat (stage 2) Clinical Trial Protocol Final version 8.0 dated 18 March 2020 Version / Date Page 1 of 90 Protocol template_Version 1.2 DNDi-SOF/RDV-01-HCV Protocol version 8.0 dated 18 Mar 2020 CONTACT DETAILS 1. Sponsor's medical expert for the trial Medically qualified DNDi Officer Dr. Isabelle Andrieux-Meyer Head of the HCV and Paediatric HIV Clinical Programs Drugs for Neglected Diseases initiative 15 Chemin Louis Dunant, 1202 Geneva, Switzerland Phone: +41 22 906 92 68 2.